Jacob Parrick, MD
Psychiatry · Scranton, PANPI 1730747858
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,273 of the $110,317 with a category attached, or 92.7%. 16 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 49.5% of the total. 2025 is the largest year on record at $101,316, more than ten times the $87 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $309.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$55K
- Axsome Therapeutics, Inc.$28K
- AbbVie$18K
- Johnson & Johnson$8K
- Otsuka America Pharmaceutical, Inc.$843
- Lundbeck LLC$367
- plus $986 from 10 others
What the payments were for
- Consulting fees$4600%
- Speaking & faculty fees$102,27393%
- Travel & lodging$2,2272%
- Food & beverage$5,1475%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 114 | $54,635 |
| Axsome Therapeutics, Inc. | 31 | $27,683 |
| AbbVie | 45 | $18,074 |
| Johnson & Johnson | 32 | $7,729 |
| Otsuka America Pharmaceutical, Inc. | 42 | $843 |
| Lundbeck LLC | 29 | $367 |
| Neurocrine Biosciences, Inc. | 24 | $249 |
| Vanda Pharmaceuticals Inc. | 13 | $225 |
| Alkermes, Inc. | 8 | $188 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Neuronetics, Inc. | 2 | $49 |
| Almatica Pharma LLC | 2 | $39 |
| Sage Therapeutics, LLC | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$28,693
- Auvelity$27,068
- Austedo XR$24,599
- VRAYLAR$17,625
- SPRAVATO$7,392
How this compares
$110,317 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $261,754 |
| Invega SustennaPaliperidone Palmitate | 89 | $257,779 |
| Austedo XrDeutetrabenazine | 19 | $245,360 |
| AustedoDeutetrabenazine | 13 | $156,468 |
| VraylarCariprazine Hcl | 68 | $94,746 |
| RexultiBrexpiprazole | 45 | $64,501 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $37,325 |
| SpravatoEsketamine Hcl | 13 | $29,748 |
| CaplytaLumateperone Tosylate | 12 | $20,915 |
| Clozapine | 240 | $20,715 |
| TrintellixVortioxetine Hydrobromide | 29 | $16,736 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $13,198 |
| Lurasidone Hcl | 50 | $11,432 |
| Clomipramine Hcl | 14 | $8,892 |
| Ramelteon | 52 | $6,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $54,635 | $401,82832 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $7,729 | $287,527102 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $249 | $261,75432 claims |
| AbbVieVraylar | $18,074 | $94,74668 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $843 | $64,50145 claims |
| Alkermes, Inc.Lybalvi | $188 | $37,32523 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $73 | $20,91512 claims |
| Axsome Therapeutics, Inc.Auvelity | $27,683 | $13,19813 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $1,324223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Scranton
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.